Summary
Seres Therapeutics' SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study
Seres Therapeutics NASDAQ: MCRB reported results from an investigator-sponsored study of SER-155 in immune checkpoint inhibitor-related enterocolitis, or irEC, saying the data support further evaluation of the live biotherapeutic as a potential non-immunosuppressive treatment option for cancer patients experiencing the gastrointestinal toxicity.
Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough
Seres Therapeutics's VOWST divestiture injected cash, retired debt, and refocused the company as a clinical‑stage microbiome specialist. Their current lead candidate is SER‑155, which seems to reduce bloodstream infections up to 77% according to their Phase 1b trial. SER-155 also holds the FDA's Breakthrough and Fast Track designations. MCRB targets more interim Phase 2 SER‑155 data within 12 months.
Serina Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Hui Fai Tam Caitong International Asset Management Co. Ltd. | 3,982 | $7,725 | $8,680.76 | $955.76 | 12.37% |
 Christopher C. Powers Farther Finance Advisors, LLC | 1 | $2 | $2.18 | $0.18 | 9% |
| MA Marie-Andree Alain Federation des caisses Desjardins du Quebec | 1 | $2 | $2.18 | $0.18 | 9% |
Serina Therapeutics Inc. (SER) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Serina Therapeutics Inc. ever had a stock split?
Serina Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Steven A. Ledger CEO | AMEX Exchange | 81751A108 CUSIP |
| US Country | 16 Employees | - Last Dividend | 15 Mar 2024 Last Split | - IPO Date |
Overview
Serina Therapeutics, Inc. is a pioneering biotechnology firm grounded in Huntsville, Alabama, focused on formulating innovative drug therapies for neurological diseases and pain management. Established in 2006, the company has been at the forefront of developing novel treatments utilizing its proprietary POZ technology. This cutting-edge approach is aimed at enhancing drug delivery, targeting persistent health issues like Parkinson's disease, epilepsy, and providing long-lasting pain relief solutions. Moreover, Serina Therapeutics, Inc. extends its technological advancements into the realm of infectious disease prevention by developing lipid nanoparticle delivered ribonucleic acid (RNA) vaccines, showcasing its versatility in the fast-evolving biotech landscape.
Products and Services
- SER 252: A POZ conjugate designed specifically for treating Parkinson's disease. SER 252 exemplifies the company's commitment to combating neurological disorders by targeting the underlying causes of this debilitating condition.
- SER 227: This product is focused on long-acting pain relief. SER 227 represents Serina Therapeutics' venture into pain management, promising a novel approach to long-term pain management strategies.
- SER 214: Another pioneering treatment aiming to tackle Parkinson's disease, SER 214 underscores the company's dedication to addressing this challenging neurological disorder through innovative therapeutic interventions.
- SER 228: In the fight against epilepsy, SER 228 is being developed as a groundbreaking treatment option. Through this product, Serina Therapeutics, Inc. endeavors to provide effective solutions to those living with epilepsy.
- POZ Technology in Lipid Nanoparticle Delivered Ribonucleic Acid (RNA) Vaccines: Apart from neurological and pain management solutions, the company is also making strides in protecting against infectious diseases through the development of RNA vaccines. This initiative highlights its adaptability and foresight in leveraging its POZ technology for broader medical applications, particularly in the area of infectious diseases prevention.
